Literature DB >> 12931207

Presynaptic proteins in the prefrontal cortex of patients with schizophrenia and rats with abnormal prefrontal development.

N D Halim1, C S Weickert, B W McClintock, T M Hyde, D R Weinberger, J E Kleinman, B K Lipska.   

Abstract

Dysfunction of the prefrontal cortex in schizophrenia may be associated with abnormalities in synaptic structure and/or function and reflected in altered concentrations of proteins in presynaptic terminals and involved in synaptic plasticity (synaptobrevin/ vesicle-associated membrane protein (VAMP), synaptosomal-associated protein-25 (SNAP-25), syntaxin, synaptophysin and growth-associated protein-43 (GAP-43)). We examined the immunoreactivity of these synapse-associated proteins via quantitative immunoblotting in the prefrontal cortex of patients with schizophrenia (n=18) and in normal controls (n=23). We also tested the stability of these proteins across successive post-mortem intervals in rat brains (at 0, 3, 12, 24, 48, and 70 h). To investigate whether experimental manipulation of prefrontal cortical development in the rat alters prefrontal synaptic protein levels, we lesioned the ventral hippocampus of rats on postnatal day 7 and measured immunoreactivity of presynaptic proteins in the prefrontal cortex on postnatal day 70. VAMP immunoreactivity was lower in the schizophrenic patients by 22% (P<0.03). There were no differences in the immunoreactivity of any other proteins measured in schizophrenic patients as compared to the matched controls. Proteins were fairly stable up to 24 h and thereafter the abundance of most proteins examined was significantly reduced (falling to as low as 20% of baseline levels at 48-70 h). VAMP immunoreactivity was higher in the lesioned rats as compared to sham controls by 22% (P&amp;<0.03). There were no significant differences between the lesioned rats and sham animals in any other presynaptic protein. These data suggest that apparently profound prefrontal cortical dysfunction in schizophrenia, as well as in an animal model of schizophrenia, may exist without gross changes in the abundance of many synaptic proteins but discrete changes in selected presynaptic molecules may be present.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12931207     DOI: 10.1038/sj.mp.4001319

Source DB:  PubMed          Journal:  Mol Psychiatry        ISSN: 1359-4184            Impact factor:   15.992


  40 in total

1.  Expression of the NR2B-NMDA receptor trafficking complex in prefrontal cortex from a group of elderly patients with schizophrenia.

Authors:  L V Kristiansen; B Bakir; V Haroutunian; J H Meador-Woodruff
Journal:  Schizophr Res       Date:  2010-03-29       Impact factor: 4.939

Review 2.  Molecular profiling of antipsychotic drug function: convergent mechanisms in the pathology and treatment of psychiatric disorders.

Authors:  Elizabeth A Thomas
Journal:  Mol Neurobiol       Date:  2006-10       Impact factor: 5.590

3.  Increased SNARE Protein-Protein Interactions in Orbitofrontal and Anterior Cingulate Cortices in Schizophrenia.

Authors:  Alfredo Ramos-Miguel; Clare L Beasley; Andrew J Dwork; J John Mann; Gorazd Rosoklija; Alasdair M Barr; William G Honer
Journal:  Biol Psychiatry       Date:  2014-12-19       Impact factor: 13.382

4.  Reduced SNAP25 Protein Fragmentation Contributes to SNARE Complex Dysregulation in Schizophrenia Postmortem Brain.

Authors:  Alfredo Ramos-Miguel; Kristina Gicas; Jehan Alamri; Clare L Beasley; Andrew J Dwork; J John Mann; Gorazd Rosoklija; Fang Cai; Weihong Song; Alasdair M Barr; William G Honer
Journal:  Neuroscience       Date:  2018-12-21       Impact factor: 3.590

Review 5.  The glutamate hypothesis of schizophrenia: evidence from human brain tissue studies.

Authors:  Wei Hu; Matthew L MacDonald; Daniel E Elswick; Robert A Sweet
Journal:  Ann N Y Acad Sci       Date:  2014-10-14       Impact factor: 5.691

6.  Altered vesicular glutamate transporter expression in the anterior cingulate cortex in schizophrenia.

Authors:  Akin Oni-Orisan; Lars V Kristiansen; Vahram Haroutunian; James H Meador-Woodruff; Robert E McCullumsmith
Journal:  Biol Psychiatry       Date:  2007-12-26       Impact factor: 13.382

7.  Associations of SNAP-25 polymorphisms with cognitive dysfunctions in Caucasian patients with schizophrenia during a brief trail of treatment with atypical antipsychotics.

Authors:  Ilja Spellmann; Norbert Müller; Richard Musil; Peter Zill; Anette Douhet; Sandra Dehning; Anja Cerovecki; Brigitta Bondy; Hans-Jürgen Möller; Michael Riedel
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2008-03-17       Impact factor: 5.270

8.  Differential expression of presynaptic genes in a rat model of postnatal hypoxia: relevance to schizophrenia.

Authors:  J U Sommer; A Schmitt; M Heck; E L Schaeffer; M Fendt; M Zink; K Nieselt; S Symons; G Petroianu; A Lex; M Herrera-Marschitz; R Spanagel; P Falkai; P J Gebicke-Haerter
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2010-10-14       Impact factor: 5.270

9.  Functional analysis of genetic variation in catechol-O-methyltransferase (COMT): effects on mRNA, protein, and enzyme activity in postmortem human brain.

Authors:  Jingshan Chen; Barbara K Lipska; Nader Halim; Quang D Ma; Mitsuyuki Matsumoto; Samer Melhem; Bhaskar S Kolachana; Thomas M Hyde; Mary M Herman; Jose Apud; Michael F Egan; Joel E Kleinman; Daniel R Weinberger
Journal:  Am J Hum Genet       Date:  2004-09-27       Impact factor: 11.025

10.  Glutamatergic deficits and parvalbumin-containing inhibitory neurons in the prefrontal cortex in schizophrenia.

Authors:  B K Y Bitanihirwe; M P Lim; J F Kelley; T Kaneko; T U W Woo
Journal:  BMC Psychiatry       Date:  2009-11-16       Impact factor: 3.630

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.